RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Torii Pharmaceutical Co Stock

Torii Pharmaceutical Co Revenue 2024

Torii Pharmaceutical Co Revenue

58.38 B JPY

Ticker

4551.T

ISIN

JP3635800000

WKN

887536

In 2024, Torii Pharmaceutical Co's sales reached 58.38 B JPY, a 6.85% difference from the 54.64 B JPY sales recorded in the previous year.

The Torii Pharmaceutical Co Revenue history

YEARREVENUE (undefined JPY)GROSS MARGIN (%)
2026e67.5736,69
2025e61.8340,09
2024e58.3842,47
202354.6445,37
202248.947,82
202146.9951,80
202041.752,13
20194351,85
201862.5549,09
201764.1451,21
201660.2149,69
201562.3850,60
201443.552,68
201358.1154,80
201252.2956,32
201148.7257,84
201045.3358,97
200942.4162,31
200837.3563,46
200740.8460,13
200639.5861,03
200540.4862,99
200441.9162,63

Torii Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Torii Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Torii Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Torii Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Torii Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Torii Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Torii Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Torii Pharmaceutical Co’s growth potential.

Torii Pharmaceutical Co Revenue, EBIT and net profit per share

DateTorii Pharmaceutical Co RevenueTorii Pharmaceutical Co EBITTorii Pharmaceutical Co Net Income
2026e67.57 B undefined0 undefined6.8 B undefined
2025e61.83 B undefined0 undefined5.71 B undefined
2024e58.38 B undefined0 undefined4.93 B undefined
202354.64 B undefined5.04 B undefined4.12 B undefined
202248.9 B undefined5.54 B undefined3.94 B undefined
202146.99 B undefined4.66 B undefined3.37 B undefined
202041.7 B undefined4.74 B undefined3.5 B undefined
201943 B undefined1.43 B undefined27.37 B undefined
201862.55 B undefined4.95 B undefined1.16 B undefined
201764.14 B undefined6.28 B undefined4.72 B undefined
201660.21 B undefined3.82 B undefined2.84 B undefined
201562.38 B undefined4.92 B undefined3.53 B undefined
201443.5 B undefined4.03 B undefined2.42 B undefined
201358.11 B undefined4.99 B undefined3.35 B undefined
201252.29 B undefined2.79 B undefined1.85 B undefined
201148.72 B undefined4.15 B undefined2.61 B undefined
201045.33 B undefined1.85 B undefined937 M undefined
200942.41 B undefined6.13 B undefined3.64 B undefined
200837.35 B undefined4.9 B undefined3.48 B undefined
200740.84 B undefined5.11 B undefined2.97 B undefined
200639.58 B undefined5.3 B undefined3.03 B undefined
200540.48 B undefined7.53 B undefined4.15 B undefined
200441.91 B undefined8.45 B undefined5.77 B undefined

Torii Pharmaceutical Co stock margins

The Torii Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Torii Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Torii Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Torii Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Torii Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Torii Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Torii Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Torii Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Torii Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Torii Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Torii Pharmaceutical Co Margin History

Torii Pharmaceutical Co Gross marginTorii Pharmaceutical Co Profit marginTorii Pharmaceutical Co EBIT marginTorii Pharmaceutical Co Profit margin
2026e45.37 %0 %10.06 %
2025e45.37 %0 %9.24 %
2024e45.37 %0 %8.45 %
202345.37 %9.22 %7.54 %
202247.82 %11.33 %8.07 %
202151.8 %9.91 %7.18 %
202052.13 %11.36 %8.38 %
201951.85 %3.33 %63.65 %
201849.09 %7.92 %1.86 %
201751.21 %9.79 %7.36 %
201649.69 %6.34 %4.72 %
201550.6 %7.89 %5.65 %
201452.68 %9.27 %5.56 %
201354.8 %8.58 %5.77 %
201256.32 %5.34 %3.54 %
201157.84 %8.53 %5.36 %
201058.97 %4.08 %2.07 %
200962.31 %14.45 %8.59 %
200863.46 %13.13 %9.31 %
200760.13 %12.51 %7.26 %
200661.03 %13.38 %7.65 %
200562.99 %18.6 %10.26 %
200462.63 %20.16 %13.77 %

Torii Pharmaceutical Co Aktienanalyse

What does Torii Pharmaceutical Co do?

Torii Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1921. The company is headquartered in Tokyo and employs over 1,200 employees. Torii specializes in the development and manufacturing of medicines for the treatment of diseases such as diabetes, cancer, kidney and liver diseases, as well as allergic diseases and mental disorders. The business model of Torii is based on developing and manufacturing innovative medicines that have a high benefit for patients. To achieve this, the company invests a large portion of its revenue in research and development of new drugs. The goal is to improve both the quality of life of patients and support society by creating new healing opportunities. Torii is divided into two business segments: Pharma and Nutraceuticals. In the Pharma segment, the company produces prescription drugs that are primarily sold in Japanese hospitals and clinics. On the other hand, the Nutraceutical division offers products that are sold without a prescription and focus on dietary supplements and health-promoting products. Torii has a wide range of products, ranging from various medications to dietary supplements and functional foods. One of Torii's most well-known products is an antidiabetic called "Trelagliptin". The medication is used to treat type 2 diabetes and is the best-selling diabetes medication in Japan. Another important product from Torii is "UFT™", a chemotherapy treatment for cancer. UFT™ is particularly effective in treating stomach, colon, and lung cancer. Another significant medication is "Micardis™", a blood pressure-lowering medication. The medication lowers blood pressure without unwanted side effects and is also available in Europe and the United States. In the Nutraceutical division, Torii offers various products such as vitamins, minerals, dietary supplements, functional foods, and beverages. One highlight is "Real Gold Three", a dietary supplement that contains eight valuable herbs and focuses on improving the immune system. The product is sold in both Japan and China. In recent years, the company has established strategic partnerships with various other companies to promote innovation and accelerate growth. In 2019, the company signed a collaboration agreement with the Vietnamese division of the British pharmaceutical giant GlaxoSmithKline (GSK). The goal of the collaboration is to strengthen the distribution of GSK products in the Vietnamese market. Torii sees itself not only as a pharmaceutical company but also as part of society. The company actively supports social projects and corporate social responsibility (CSR). For example, Torii supports the "Operation Smile" program, which aims to help children with cleft lips and palates. Overall, Torii is an important player in the Japanese pharmaceutical market specializing in research, development, and marketing of innovative medicines. The company has a broad portfolio and has expanded its product range in recent years with various high-quality products. With its partnerships and social initiatives, Torii demonstrates that it is not only a commercial company but also makes an important contribution to society and the health of people. Torii Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Torii Pharmaceutical Co's Sales Figures

The sales figures of Torii Pharmaceutical Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Torii Pharmaceutical Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Torii Pharmaceutical Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Torii Pharmaceutical Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Torii Pharmaceutical Co stock

How much revenue did Torii Pharmaceutical Co generate this year?

Torii Pharmaceutical Co has achieved a revenue of 58.38 B JPY this year.

How much was the turnover of the company Torii Pharmaceutical Co compared to the previous year?

The revenue of Torii Pharmaceutical Co has increased by 6.85% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Torii Pharmaceutical Co?

The revenue of Torii Pharmaceutical Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Torii Pharmaceutical Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Torii Pharmaceutical Co so important for investors?

The revenue of Torii Pharmaceutical Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Torii Pharmaceutical Co pay?

Over the past 12 months, Torii Pharmaceutical Co paid a dividend of 120 JPY . This corresponds to a dividend yield of about 3.51 %. For the coming 12 months, Torii Pharmaceutical Co is expected to pay a dividend of 121.66 JPY.

What is the dividend yield of Torii Pharmaceutical Co?

The current dividend yield of Torii Pharmaceutical Co is 3.51 %.

When does Torii Pharmaceutical Co pay dividends?

Torii Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

How secure is the dividend of Torii Pharmaceutical Co?

Torii Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Torii Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 121.66 JPY are expected. This corresponds to a dividend yield of 3.56 %.

In which sector is Torii Pharmaceutical Co located?

Torii Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Torii Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Torii Pharmaceutical Co from 3/1/2025 amounting to 60 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Torii Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 3/1/2025.

What was the dividend of Torii Pharmaceutical Co in the year 2023?

In the year 2023, Torii Pharmaceutical Co distributed 100 JPY as dividends.

In which currency does Torii Pharmaceutical Co pay out the dividend?

The dividends of Torii Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Torii Pharmaceutical Co

Our stock analysis for Torii Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Torii Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.